ArticleEuropean oral research2026
In vitro evaluation of antimicrobial and cytotoxic activity of newly synthesized and characterized nanocurcumin.
Article in European oral research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Curcumin, the principal curcuminoid found in turmeric, demonstrates potent antibacterial and anti-inflammatory characteristics; nevertheless, it possesses restricted solubility and bioavailability. Numerous studies have reported elevated bioavailability and antimicrobial activity of nano-formulations of curcumin. Porphyromonas gingivalis plays a crucial role in triggering dysbiosis in the subgingival milieu, leading to the progression of periodontitis. This work details nanocurcumin preparation, characterization, and in vitro evaluation of antibacterial activity against Porphyromonas gingivalis and its cytotoxic effects on L929 mouse embryo fibroblasts. Materials and methods: Nanocurcumin was prepared using the antisolvent precipitation method and characterized by Scanning electron microscopy, UV-visible spectrophotometry, Fourier transform infrared spectroscopy, and Nuclear Magnetic Resonance. The antimicrobial activity of nanocurcumin against Porphyromonas gingivalis was assessed using the minimum inhibitory concentration (MIC). Cytotoxicity against L929 mouse embryo fibroblasts was evaluated with the MTT assay. Results: Nanocurcumin exhibited significant water solubility, nanoparticle size ranging from 18 to 176 nm, a strong absorbance peak at 425nm, and a comparable chemical structure to curcumin. MIC of nanocurcumin was 6.25 µg/ml compared to 25 µg/ml of curcumin and 3.12 µg/ml of tetracycline. Both nanocurcumin and curcumin demonstrated a dose-dependent negative impact on L929 fibroblasts with IC50 concentrations of 86.16 µg/ml and 45.69 µg/ml respectively. Conclusion: Nanocurcumin in the present study demonstrates well-characterized nanoparticle formation with excellent antimicrobial activity against Porphyromonas gingivalis and minimal cytotoxicity against L929 cell line. Nanocurcumin demonstrates significant promise for integration into drug delivery systems for the management of periodontal disease, subject to additional experimental and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.